Cutaneous vaccination ameliorates Zika virus-induced neuro-ocular pathology via reduction of anti-ganglioside antibodies

• Autores principales: Jacob T. Beaver (Autor), Lisa K. Mills (Autor), Dominika Swieboda (Autor), Nadia Lelutiu (Autor), Edward S. Esser (Autor), Olivia Q. Antao (Autor), Eugenia Scountzou (Autor), Dahnide T. Williams (Autor), Nikolaos Papaioannou (Autor), Elizabeth Q. Littauer (Autor), Andrey Romanyuk (Autor), Richard W. Compans (Autor), Mark R. Prausnitz (Autor), Ioanna Skountzou (Autor)
• Formato: Libro
• Publicado: Taylor & Francis Group, 2020-09-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Zika virus (ZIKV) causes moderate to severe neuro-ocular sequelae, with symptoms ranging from conjunctivitis to Guillain-Barré Syndrome (GBS). Despite the international threat ZIKV poses, no licensed vaccine exists. As ZIKV and DENV are closely related, antibodies against one virus have demonstrated...